AIDS and Behavior

, Volume 18, Issue 7, pp 1199–1223 | Cite as

Impact of Geographic and Transportation-Related Barriers on HIV Outcomes in Sub-Saharan Africa: A Systematic Review

  • Alexander J. Lankowski
  • Mark J. Siedner
  • David R. Bangsberg
  • Alexander C. Tsai
Substantive Review

Abstract

Difficulty obtaining reliable transportation to clinic is frequently cited as a barrier to HIV care in sub-Saharan Africa (SSA). Numerous studies have sought to characterize the impact of geographic and transportation-related barriers on HIV outcomes in SSA, but to date there has been no systematic attempt to summarize these findings. In this systematic review, we summarized this body of literature. We searched for studies conducted in SSA examining the following outcomes in the HIV care continuum: (1) voluntary counseling and testing, (2) pre-antiretroviral therapy (ART) linkage to care, (3) loss to follow-up and mortality, and (4) ART adherence and/or viral suppression. We identified 34 studies containing 52 unique estimates of association between a geographic or transportation-related barrier and an HIV outcome. There was an inverse effect in 23 estimates (44 %), a null association in 26 (50 %), and a paradoxical beneficial impact in 3 (6 %). We conclude that geographic and transportation-related barriers are associated with poor outcomes across the continuum of HIV care.

Keywords

Transportation barriers Linkage to care Retention in care Adherence Sub-Saharan Africa 

Resúmen

Las dificultades para obtener un transporte confiable a la clínica son frecuentemente citadas como una barrera para la atención del VIH en el África subsahariana; sin embargo, la magnitud de este efecto es desconocido. En esta reseña sistemática, resumimos la literatura sobre el impacto de las barreras geográficas y de transporte en los resultados relacionados con el VIH en el África subsahariana. Se buscaron estudios realizados en el África subsahariana examinando los siguientes resultados en el continuo de la atención del VIH: 1) asesoramiento y pruebas voluntarias, 2) vinculo a los servicios antes de empezar el tratamiento antirretroviral (ART), 3) pérdida en el seguimiento y la mortalidad, y 4) adherencia al ART y/o la supresión viral. Se identificaron 34 estudios que contienen 52 estimaciones únicas de asociación entre una barrera geográfica o relacionados al transporte y el resultado de VIH. Se produjo un efecto adverso en 23 estimaciones (44 %), una asociación nula en 26 (50 %), y un impacto paradójico beneficioso en 3 (6 %). Se concluyó que las barreras geográficas y relacionadas con el transporte están asociadas con resultados pobres de todo el continuo de la atención del VIH.

References

  1. 1.
    Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Cain LE, Logan R, Robins JM, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med. 2011;154(8):509–15.PubMedCrossRefGoogle Scholar
  3. 3.
    Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363(3):257–65.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Maman D, Pujades-Rodriguez M, Nicholas S, et al. Response to antiretroviral therapy: improved survival associated with CD4 above 500 cells/ml. AIDS. 2012;26(11):1393–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57.PubMedCrossRefGoogle Scholar
  6. 6.
    Hammer SM. Antiretroviral treatment as prevention. N Engl J Med. 2011;365(6):561–2.PubMedCrossRefGoogle Scholar
  7. 7.
    Geng EH, Hare CB, Kahn JO, et al. The effect of a “universal antiretroviral therapy” recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/mL in a public health setting. Clin Infect Dis. 2012;55(12):1690–7.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    World Health Organization, UNAIDS, UNICEF. Global HIV/AIDS response: epidemic update and health sector progress towards Universal Access; 2011.Google Scholar
  9. 9.
    Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817–24.PubMedCrossRefGoogle Scholar
  10. 10.
    Brinkhof MW, Spycher BD, Yiannoutsos C, et al. Adjusting mortality for loss to follow-up: analysis of five ART programmes in sub-Saharan Africa. PLoS ONE. 2010;5(11):e14149.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Gupta A, Nadkarni G, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS ONE. 2011;6(12):e28691.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22(15):1897–908.PubMedCrossRefGoogle Scholar
  13. 13.
    Marazzi MC, Liotta G, Germano P, et al. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retrovir. 2008;24(4):555–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Kigozi IM, Dobkin LM, Martin JN, et al. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in sub-Saharan Africa. J Acquir Immune Defic Syndr. 2009;52(2):280–9.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Katz IT, Essien T, Marinda ET, et al. Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS. 2011;25(17):2177–81.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Losina E, Bassett IV, Giddy J, et al. The “ART” of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS ONE. 2010;5(3):e9538.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Bassett IV, Regan S, Chetty S, et al. Who starts antiretroviral therapy in Durban, South Africa?… not everyone who should. AIDS. 2010;24(Suppl 1):S37–44.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4(10):e298.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Geng EH, Nash D, Kambugu A, et al. Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep. 2010;7(4):234–44.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007;21(8):965–71.PubMedCrossRefGoogle Scholar
  21. 21.
    Eisenberg JM, Power EJ. Transforming insurance coverage into quality health care: voltage drops from potential to delivered quality. JAMA. 2000;284(16):2100–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav. 2010;14(4):778–84.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Biadgilign S, Deribew A, Amberbir A, Deribe K. Barriers and facilitators to antiretroviral medication adherence among HIV-infected paediatric patients in Ethiopia: a qualitative study. SAHARA J. 2009;6(4):148–54.PubMedCrossRefGoogle Scholar
  24. 24.
    Hardon AP, Akurut D, Comoro C, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19(5):658–65.PubMedCrossRefGoogle Scholar
  25. 25.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS. 2012;26(16):2059–67.PubMedCrossRefGoogle Scholar
  27. 27.
    Hutchinson PL, Mahlalela X. Utilization of voluntary counseling and testing services in the Eastern Cape, South Africa. AIDS Care. 2006;18(5):446–55.PubMedCrossRefGoogle Scholar
  28. 28.
    Kaawa-Mafigiri D, Mcgrath J, Namutiibwa F, et al. Delays in seeking HIV/AIDS testing and treatment among patients on ARVs in urban (Kampala) and rural southwestern Uganda. XIX International AIDS Conference. Washington, DC, 2012.Google Scholar
  29. 29.
    Morin SF, Khumalo-Sakutukwa G, Charlebois ED, et al. Removing barriers to knowing HIV status: same-day mobile HIV testing in Zimbabwe. J Acquir Immune Defic Syndr. 2006;41(2):218–24.PubMedCrossRefGoogle Scholar
  30. 30.
    Minstry of Health Uganda, ORC Macro. Uganda HIV/AIDS sero-behavioural survey 2004–2005. Calverton: Ministry of Health and ORC Macro; 2006.Google Scholar
  31. 31.
    Amuron B, Namara G, Birungi J, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Parkes-Ratanshi R, Bufumbo L, Nyanzi-Wakholi B, et al. Barriers to starting ART and how they can be overcome: individual and operational factors associated with early and late start of treatment. Trop Med Int Health. 2010;15(11):1347–56.PubMedCrossRefGoogle Scholar
  33. 33.
    Braitstein P, Songok J, Vreeman RC, et al. “Wamepotea” (they have become lost): outcomes of HIV-positive and HIV-exposed children lost to follow-up from a large HIV treatment program in western Kenya. J Acquir Immune Defic Syndr. 2011;57(3):e40–6.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Krebs DW, Chi BH, Mulenga Y, et al. Community-based follow-up for late patients enrolled in a district-wide programme for antiretroviral therapy in Lusaka, Zambia. AIDS Care. 2008;20(3):311–7.PubMedCrossRefGoogle Scholar
  35. 35.
    McGuire M, Munyenyembe T, Szumilin E, et al. Vital status of pre-ART and ART patients defaulting from care in rural Malawi. Trop Med Int Health. 2010;15(Suppl 1):55–62.PubMedCrossRefGoogle Scholar
  36. 36.
    Ochieng-Ooko V, Ochieng D, Sidle JE, et al. Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ. 2010;88(9):681–8.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Adeyemo A, Tamen F, Ayebe T, Oyigebe G. Socio-gender factors as explanation for poor drug adherence among antiretroviral users. 4th International Conference on HIV Treatment Adherence. Miami; 2009.Google Scholar
  38. 38.
    Asiimwe B, Tarinyeba E, Kyomuhendo J. Adherence results for 84 patients on anti-retroviral therapy for 1 year at Bushenyi Medical Centre, Katungu in rural south western Uganda. 2nd International Conference on HIV Treatment Adherence. Miami; 2007.Google Scholar
  39. 39.
    Bajunirwe F, Tisch DJ, King CH, Arts EJ, Debanne SM, Sethi AK. Quality of life and social support among patients receiving antiretroviral therapy in Western Uganda. AIDS Care. 2009;21(3):271–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Eholie SP, Tanon KA, Folquet-Amorissani M, et al. Impact of access to antiretroviral therapy in Cote d’Ivoire. Med Trop (Mars). 2009;69(5):520–4.PubMedGoogle Scholar
  41. 41.
    Kip E, Ehlers VJ, van der Wal DM. Patients’ adherence to anti-retroviral therapy in Botswana. J Nurs Scholarsh. 2009;41(2):149–57.PubMedCrossRefGoogle Scholar
  42. 42.
    Kirsten I, Sewangi J, Kunz A, et al. Adherence to combination prophylaxis for prevention of mother-to-child-transmission of HIV in Tanzania. PLoS ONE. 2011;6(6):e21020.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Munseri PJ, Talbot EA, Mtei L, von Reyn CF. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis. 2008;12(9):1037–41.PubMedGoogle Scholar
  44. 44.
    Olowookere SA, Fatiregun AA, Akinyemi JO, Bamgboye AE, Osagbemi GK. Prevalence and determinants of nonadherence to highly active antiretroviral therapy among people living with HIV/AIDS in Ibadan, Nigeria. J Infect Dev Ctries. 2008;2(5):369–72.PubMedGoogle Scholar
  45. 45.
    Potchoo Y, Tchamdja K, Balogou A, Pitche VP, Guissou IP, Kassang EK. Knowledge and adherence to antiretroviral therapy among adult people living with HIV/AIDS treated in the health care centers of the association “Espoir Vie Togo” in Togo, West Africa. BMC Clin Pharmacol. 2010;10:11.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    van Dijk JH, Sutcliffe CG, Munsanje B, Hamangaba F, Thuma PE, Moss WJ. Barriers to the care of HIV-infected children in rural Zambia: a cross-sectional analysis. BMC Infect Dis. 2009;9:169.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Weiser S, Wolfe W, Bangsberg D, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003;34(3):281–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Yahaya H, Gwarzo U, Liman MS. Forecasting long-term adherence to HAART in GHAIN-supported facility using client’s socioeconomic status. 1st International Conference on HIV Treatment Adherence. Miami; 2006.Google Scholar
  49. 49.
    Assefa Y, Van Damme W, Mariam DH, Kloos H. Toward universal access to HIV counseling and testing and antiretroviral treatment in Ethiopia: looking beyond HIV testing and ART initiation. AIDS Patient Care STDS. 2010;24(8):521–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Bowie C, Gondwe N. Changing clinical needs of people living with AIDS and receiving home based care in Malawi: the Bangwe Home Based Care Project 2003–2008—a descriptive study. BMC Public Health. 2010;10:370–1.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Chan AK, van Lettow M, Tenthani L, et al. Outcome assessment of a dedicated HIV positive health care worker clinic at a central hospital in Malawi: a retrospective observational study. PLoS One. 2011;6(5):e19789.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Lubega M, Nsabagasani X, Tumwesigye NM, et al. Policy and practice, lost in transition: reasons for high drop-out from pre-antiretroviral care in a resource-poor setting of eastern Uganda. Health Policy. 2010;95(2–3):153–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Bwirire LD, Fitzgerald M, Zachariah R, et al. Reasons for loss to follow-up among mothers registered in a prevention-of-mother-to-child transmission program in rural Malawi. Trans R Soc Trop Med Hyg. 2008;102(12):1195–200.PubMedCrossRefGoogle Scholar
  54. 54.
    Abrahams N, Jewkes R. Barriers to post exposure prophylaxis (PEP) completion after rape: a South African qualitative study. Cult Health Sex. 2010;12(5):471–84.PubMedCrossRefGoogle Scholar
  55. 55.
    Byakika-Tusiime J, Crane J, Oyugi JH, et al. Longitudinal antiretroviral adherence in HIV+Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time. AIDS Behav. 2009;13(Suppl 1):82–91.PubMedCrossRefGoogle Scholar
  56. 56.
    Nam SL, Fielding K, Avalos A, Dickinson D, Gaolathe T, Geissler PW. The relationship of acceptance or denial of HIV-status to antiretroviral adherence among adult HIV patients in urban Botswana. Soc Sci Med. 2008;67(2):301–10.PubMedCrossRefGoogle Scholar
  57. 57.
    Nassali M, Nakanjako D, Kyabayinze D, Beyeza J, Okoth A, Mutyaba T. Access to HIV/AIDS care for mothers and children in sub-Saharan Africa: adherence to the postnatal PMTCT program. AIDS Care. 2009;21(9):1124–31.PubMedCrossRefGoogle Scholar
  58. 58.
    Peterson K, Laly R. Patterns in the use of adherence supports. 1st International Conference on HIV Treatment Adherence. Miami; 2006.Google Scholar
  59. 59.
    Pyne-Mercier LD, John-Stewart GC, Richardson BA, et al. The consequences of post-election violence on antiretroviral HIV therapy in Kenya. Aids Care. 2011;23(5):562–8.PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Rowe KA, Makhubele B, Hargreaves JR, Porter JD, Hausler HP, Pronyk PM. Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings? Int J Tuberc Lung Dis. 2005;9(3):263–9.PubMedGoogle Scholar
  61. 61.
    Thobias A, Van Wyk B. Issues in adherence to antiretroviral treatment in an urban setting in Namibia. 4th International Conference on HIV Treatment Adherence. Miami; 2009.Google Scholar
  62. 62.
    Ware NC, Idoko J, Kaaya S, et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med. 2009;6(1):e11.PubMedCrossRefGoogle Scholar
  63. 63.
    Weiser SD, Tuller DM, Frongillo EA, Senkungu J, Mukiibi N, Bangsberg DR. Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PLoS One. 2010;5(4):e10340.PubMedCentralPubMedCrossRefGoogle Scholar
  64. 64.
    Wringe A, Isingo R, Urassa M, et al. Uptake of HIV voluntary counselling and testing services in rural Tanzania: implications for effective HIV prevention and equitable access to treatment. Trop Med Int Health. 2008;13(3):319–27.PubMedCrossRefGoogle Scholar
  65. 65.
    Cook RE, Ciampa PJ, Sidat M, et al. Predictors of successful early infant diagnosis of HIV in a rural district hospital in Zambezia, Mozambique. J Acquir Immune Defic Syndr. 2011;56(4):e104–9.PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Ingle SM, May M, Uebel K, et al. Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study. AIDS. 2010;24(17):2717–25.PubMedCentralPubMedCrossRefGoogle Scholar
  67. 67.
    Lessells RJ, Mutevedzi PC, Cooke GS, Newell ML. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr. 2011;56(3):e79–86.PubMedCentralPubMedCrossRefGoogle Scholar
  68. 68.
    Sutcliffe CG, van Dijk JH, Bolton-Moore C, Cotham M, Tambatamba B, Moss WJ. Differences in presentation, treatment initiation, and response among children infected with human immunodeficiency virus in urban and rural Zambia. Pediatr Infect Dis J. 2010;29(9):849–54.PubMedCrossRefGoogle Scholar
  69. 69.
    Elbireer S, Guwatudde D, Mudiope P, Nabbuye-Sekandi J, Manabe YC. Tuberculosis treatment default among HIV-TB co-infected patients in urban Uganda. Trop Med Int Health. 2011;16(8):981–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Geng EH, Glidden DV, Bwana MB, et al. Retention in care and connection to care among HIV-infected patients on antiretroviral therapy in Africa: estimation via a sampling-based approach. PLoS One. 2011;6(7):e21797.PubMedCentralPubMedCrossRefGoogle Scholar
  71. 71.
    Karcher H, Omondi A, Odera J, Kunz A, Harms G. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health. 2007;12(5):687–94.PubMedCrossRefGoogle Scholar
  72. 72.
    Kempf MC, Allen S, Zulu I, et al. Enrollment and retention of HIV discordant couples in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2008;47(1):116–25.PubMedCrossRefGoogle Scholar
  73. 73.
    Massaquoi M, Zachariah R, Manzi M, et al. Patient retention and attrition on antiretroviral treatment at district level in rural Malawi. Trans R Soc Trop Med Hyg. 2009;103(6):594–600.PubMedCrossRefGoogle Scholar
  74. 74.
    Mossdorf E, Stoeckle M, Mwaigomole EG, et al. Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. BMC Infect Dis. 2011;11:98.PubMedCentralPubMedCrossRefGoogle Scholar
  75. 75.
    Mulissa Z, Jerene D, Lindtjorn B. Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. PLoS ONE. 2010;5(10):e13268.PubMedCentralPubMedCrossRefGoogle Scholar
  76. 76.
    Adeyemi A, Olubunmi F, Oluseyi A. Predictors of adherence for patients on highly active antiretroviral therapy in HIV treatment program. 12th Annual International Meeting of the Institute of Human Virology. Tropea; 2010.Google Scholar
  77. 77.
    Bagenda A, Barlow-Mosha L, Bagenda D, Sakwa R, Fowler MG, Musoke PM. Adherence to tablet and liquid formulations of antiretroviral medication for paediatric HIV treatment at an urban clinic in Uganda. Ann Trop Paediatr. 2011;31(3):235–45.PubMedCrossRefGoogle Scholar
  78. 78.
    Barth RE, Tempelman HA, Smelt E, Wensing AM, Hoepelman AI, Geelen SP. Long-term outcome of children receiving antiretroviral treatment in rural South Africa: substantial virologic failure on first-line treatment. Pediatr Infect Dis J. 2011;30(1):52–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV plus Ugandan patients purchasing therapy. Int J STD AIDS. 2005;16(1):38–41.PubMedCrossRefGoogle Scholar
  80. 80.
    Carlucci JG, Kamanga A, Sheneberger R, et al. Predictors of adherence to antiretroviral therapy in rural Zambia. J Acquir Immune Defic Syndr. 2008;47(5):615–22.PubMedCentralPubMedCrossRefGoogle Scholar
  81. 81.
    Charurat M, Oyegunle M, Benjamin R, et al. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS ONE. 2010;5(5):e10584.PubMedCentralPubMedCrossRefGoogle Scholar
  82. 82.
    Haberer JE, Kiwanuka J, Nansera D, Ragland K, Mellins C, Bangsberg DR. Multiple measures reveal antiretroviral adherence successes and challenges in HIV-infected Ugandan children. PLoS ONE. 2012;7(5):e36737.PubMedCentralPubMedCrossRefGoogle Scholar
  83. 83.
    Hirschhorn L, Singal R, Navario P, Mokhele I, Patel A, Maartens G. Adherence to ART in two innovative treatment models in South Africa. 4th International Conference on HIV Treatment Adherence. Miami; 2009.Google Scholar
  84. 84.
    Iroha E, Esezobor CI, Ezeaka C, Temiye EO, Akinsulie A. Adherence to antiretroviral therapy among HIV-infected children attending a donor-funded clinic at a tertiary hospital in Nigeria. AJAR-Afr J Aids Res. 2010;9(1):25–30.CrossRefGoogle Scholar
  85. 85.
    Kurlander C, Eng ML, Charurat M, Farley JJ, Blattner WA. Evaluation of pharmacy refill rates and self-reported adherence for antiretroviral therapy at a PEPFAR clinic in northern Nigeria. 2nd International Conference on HIV Treatment Adherence. Miami; 2007.Google Scholar
  86. 86.
    Maqutu D, Zewotir T, North D, Naidoo K, Grobler A. Factors affecting first-month adherence to antiretroviral therapy among HIV-positive adults in South Africa. AJAR-Afr J Aids Res. 2010;9(2):117–24.CrossRefGoogle Scholar
  87. 87.
    Mbaezue N, Farley J, Charurat M, Blattner WA. A case control study of nonadherence among Nigerian patients initiating antiretroviral (ARV) therapy. 2nd International Conference on HIV Treatment Adherence. Miami; 2007.Google Scholar
  88. 88.
    Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45(11):1492–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Sethi A, Bajunirwe F, Mafigiri D, et al. Distance as a barrier to adherence to antiretroviral therapy among HIV-infected patients in rural southwestern Uganda. 4th International Conference on HIV Treatment Adherence. Miami; 2009.Google Scholar
  90. 90.
    Taiwo BO, Idoko JA, Welty LJ, et al. Assessing the viorologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited setting. J Acquir Immune Defic Syndr. 2010;54(1):85–92.PubMedCrossRefGoogle Scholar
  91. 91.
    van Dijk JH, Sutcliffe CG, Munsanje B, et al. HIV-infected children in rural Zambia achieve good immunologic and virologic outcomes two years after initiating antiretroviral therapy. PLoS One. 2011;6(4):e19006.PubMedCentralPubMedCrossRefGoogle Scholar
  92. 92.
    Bateman J, Garrod GD, Brainard JS, Lovett AS. Measurement issues in the travel cost method: a geographical information systems approach. J Agric Econ. 1996;47(2):191–205.CrossRefGoogle Scholar
  93. 93.
    Siedner MJ, Lankowski A, Tsai AC, et al. GPS-measured distance to clinic, but not self-reported transportation factors, are associated with missed HIV clinic visits in rural Uganda. AIDS. 2013;27(9):1503–8.PubMedCentralPubMedCrossRefGoogle Scholar
  94. 94.
    Tsai AC, Bangsberg DR, Weiser SD. Harnessing poverty alleviation to reduce the stigma of HIV in Sub-Saharan Africa. PLoS Med. 2013;10(11):e1001557.PubMedCentralPubMedCrossRefGoogle Scholar
  95. 95.
    Turan JM, Bukusi EA, Onono M, Holzemer WL, Miller S, Cohen CR. HIV/AIDS stigma and refusal of HIV testing among pregnant women in rural Kenya: results from the MAMAS Study. AIDS Behav. 2011;15(6):1111–20.PubMedCentralPubMedCrossRefGoogle Scholar
  96. 96.
    Tsai AC, Bangsberg DR, Kegeles SM, et al. Internalized stigma, social distance, and disclosure of HIV seropositivity in rural Uganda. Ann Behav Med. 2013;46(3):285–94.PubMedCrossRefGoogle Scholar
  97. 97.
    Naar-King S, Bradford J, Coleman S, Green-Jones M, Cabral H, Tobias C. Retention in care of persons newly diagnosed with HIV: outcomes of the Outreach Initiative. AIDS Patient Care STDS. 2007;21(Suppl 1):S40–8.PubMedGoogle Scholar
  98. 98.
    Katz IT, Ryu AE, Onuegbu AG, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc. 2013;16(3 Suppl 2):18640.PubMedCentralPubMedGoogle Scholar
  99. 99.
    Mekonnen Y, Sanders R, Tibebu S, Emmart P. Equity and access to ART in Ethiopia. Washington, DC: Futures Group, Health Policy Initiative; 2010.Google Scholar
  100. 100.
    Mahler HR, Kileo B, Curran K, et al. Voluntary medical male circumcision: matching demand and supply with quality and efficiency in a high-volume campaign in Iringa Region, Tanzania. PLoS Med. 2011;8(11):e1001131.PubMedCentralPubMedCrossRefGoogle Scholar
  101. 101.
    Gilbert L, Walker L. ‘My biggest fear was that people would reject me once they knew my status…’: stigma as experienced by patients in an HIV/AIDS clinic in Johannesburg, South Africa. Health Soc Care Community. 2010;18(2):139–46.PubMedCrossRefGoogle Scholar
  102. 102.
    Wilson DP, Blower S. How far will we need to go to reach HIV-infected people in rural South Africa? BMC Med. 2007;5:16.PubMedCentralPubMedCrossRefGoogle Scholar
  103. 103.
    Boyer S, Eboko F, Camara M, et al. Scaling up access to antiretroviral treatment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon. AIDS. 2010;24(Suppl 1):S5–15.PubMedCrossRefGoogle Scholar
  104. 104.
    Bemelmans M, van den Akker T, Ford N, et al. Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care. Trop Med Int Health. 2010;15(12):1413–20.PubMedCrossRefGoogle Scholar
  105. 105.
    Pfeiffer J, Montoya P, Baptista AJ, et al. Integration of HIV/AIDS services into African primary health care: lessons learned for health system strengthening in Mozambique: a case study. J Int AIDS Soc. 2010;13:3.PubMedCentralPubMedCrossRefGoogle Scholar
  106. 106.
    Tsai AC, Chopra M, Pronyk PM, Martinson NA. Socioeconomic disparities in access to HIV/AIDS treatment programs in resource-limited settings. AIDS Care. 2009;21(1):59–63.PubMedCrossRefGoogle Scholar
  107. 107.
    Siedner MJ, Lankowski A, Haberer JE, et al. Rethinking the “pre” in pre-therapy counseling: no benefit of additional visits prior to therapy on adherence or viremia in Ugandans initiating ARVs. PLoS ONE. 2012;7(6):e39894.PubMedCentralPubMedCrossRefGoogle Scholar
  108. 108.
    Wilson DP, Blower SM. Designing equitable antiretroviral allocation strategies in resource-constrained countries. PLoS Med. 2005;2(2):e50.PubMedCentralPubMedCrossRefGoogle Scholar
  109. 109.
    Jani IV, Sitoe NE, Alfai ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet. 2011;378(9802):1572–9.PubMedCrossRefGoogle Scholar
  110. 110.
    Wanyenze RK, Hahn JA, Liechty CA, et al. Linkage to HIV care and survival following inpatient HIV counseling and testing. AIDS Behav. 2011;15(4):751–60.PubMedCentralPubMedCrossRefGoogle Scholar
  111. 111.
    Siedner MJ, Haberer JE, Bwana MB, Ware NC, Bangsberg DR. High acceptability for cell phone text messages to improve communication of laboratory results with HIV-infected patients in rural Uganda: a cross-sectional survey study. BMC Med Inform Decis Mak. 2012;12:56.PubMedCentralPubMedCrossRefGoogle Scholar
  112. 112.
    Emenyonu N, Thirumurthy H, Muyindike W, et al. Cash transfers to cover clinic transportation costs improve adherence and retention in care in a HIV treatment program in Rural Uganda. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco; 2010.Google Scholar
  113. 113.
    Mukherjee JS, Ivers L, Leandre F, Farmer P, Behforouz H. Antiretroviral therapy in resource-poor settings. Decreasing barriers to access and promoting adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S123–6.PubMedCrossRefGoogle Scholar
  114. 114.
    Haberer JE, Kiwanuka J, Nansera D, et al. Real-time adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda. AIDS. 2013;27(13):2166–8.PubMedCrossRefGoogle Scholar
  115. 115.
    Bachman Desilva M, Gifford AL, Keyi X, et al. Feasibility and acceptability of a real-time adherence device among HIV-positive IDU patients in China. AIDS Res Treat. 2013;2013:957862.PubMedCentralPubMedGoogle Scholar
  116. 116.
    Haberer JE, Robbins GK, Ybarra M, et al. Real-time electronic adherence monitoring is feasible, comparable to unannounced pill counts, and acceptable. AIDS Behav. 2012;16(2):375–82.PubMedCentralPubMedCrossRefGoogle Scholar
  117. 117.
    Haberer JE, Kahane J, Kigozi I, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14(6):1340–6.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Alexander J. Lankowski
    • 1
    • 2
  • Mark J. Siedner
    • 2
  • David R. Bangsberg
    • 2
    • 3
    • 4
  • Alexander C. Tsai
    • 2
    • 4
    • 5
  1. 1.Departments of Internal Medicine and PediatricsUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Center for Global HealthMassachusetts General HospitalBostonUSA
  3. 3.Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of TechnologyHarvard Medical SchoolCambridgeUSA
  4. 4.Mbarara University of Science and TechnologyMbararaUganda
  5. 5.Chester M. Pierce Division of Global Psychiatry, Department of PsychiatryMassachusetts General HospitalBostonUSA

Personalised recommendations